In a recent study19, genomic losses were also reported to be the major contributor to the first and second quartile CNA burden in men with high risk node negative (M0N0; defined as having at least two of tumour stage category T3/4, prostate-specific antigen (PSA) ≥ 40 ng/ml, or Gleason sum score 8–10) or node positive (M0N1) and metastatic (M1) PCa recruited to the control arm of the STAMPEDE trial (NCT00268476). This evidence concerns the gene KLK3 and posterior cortical atrophy.